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1 |  INTRODUCTION
Langerhans cell histiocytosis (LCH) is a rare tumor, and LCH 
may develop in the mandible in young people. LCH treat-
ment options include surgery, chemotherapy, and radiation 
therapy. In some cases, healing may occur spontaneously. We 
describe a case of LCH in the mandible of a child who expe-
rienced spontaneous regression after biopsy.
Langerhans cell histiocytosis (LCH) is a disease in which 
one type of antigen- presenting cells, the Langerhans cells, ag-
gregates and proliferates in various organs such as the bone, 
skin, liver, spleen, or lung, resulting in tissue damage,1,2 LCH 
was previously known as histiocytosis X and was classified 
into three types: eosinophilic granulomatosis, Hand- Schüller- 
Christian disease, and Letterer- Siwe disease. These are all 
characterized by the proliferation of Langerhans cells and 
have been collectively referred to as LCH.3 At present, LCH 
is classified into three groups: single- system single- site (SS 
type), single- system multi- site (SM type), and multi- system 
multi- site (MM type), and treatment differs depending on the 
location and type of disease.4 In Japan, an epidemiological 
study reported that the SS, SM, and MM types of LCH are 
diagnosed at almost equal rates.5 In patients with the SM or 
MM type, the typical treatment in Japan is multidrug chemo-
therapy following the protocol proposed by the Japan LCH 
Study Group.6 However, some SS cases experience sponta-
neous remission, and no sufficient consensus for treatment 
has yet been reached,7,8 We report a case of LCH in the man-
dible with spontaneous remission after biopsy.
2 |  CASE REPORT
A 4- year- old boy was seen by nearby pediatricians for pain-
ful swelling of his left cheek. Computed tomography (CT) and 
contrast- enhanced magnetic resonance imaging (MRI) showed 
osteolysis and mass formation in the left angle of mandible, and 
he was referred to our hospital with suspected ameloblastoma.
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Abstract
In younger patients of LCH, we should consider that the effectiveness of follow- up 
without aggressive treatment for SS- type LCH in the oral and maxillofacial bone. 
However, there are very rare case in which an SS- type LCH recurred after showing a 
healing tendency. Regular follow- up must be performed even after healing.
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At the patient's first visit, his left cheek showed painful 
swelling, and the submandibular lymph nodes were palpable, 
tender, and mobile (Figure 1). The patient's mouth opening 
capacity was only about 20 mm, and trismus was recognized.
CT imaging showed osteolysis with indistinct borders 
in the left mandibular ramus, and rupture was observed in 
the buccolingual cortical bone (Figure  2A,B). A perios-
teal reaction was also observed on the buccolingual side. 
Contrast- enhanced MRI T1- weighted images showed that 
a contrast- enhancing mass had spread outside the bone on 
the buccolingual side, and inflammatory edema changed in 
the surrounding soft tissue (Figure  2C). An unstained area 
was observed inside the lesion on a T1- weighted image. 
Bone scintigraphy showed abnormal accumulation only in 
the left mandible (Figure  2D). Positron emission tomogra-
phy (PET)- CT also showed abnormal accumulation of 18F- 
fluorodeoxyglucose (FDG) (SUVmax = 4.90) only in the left 
mandible (Figure 2E,F). These imaging findings were atyp-
ical for ameloblastoma. The clinical differential diagnosis 
included LCH, myeloma, lymphoma, and plasmacytoma, 
but all were atypical and histopathological examination was 
required.
To establish a diagnosis, an incisional biopsy was per-
formed under general anesthesia (Figure 3). Specifically, after 
infiltration anesthesia, a mucosal periosteal flap was created 
by making an incision in the distal direction from the buccal 
gingiva of the left mandibular second deciduous molar along 
the lateral oblique line. When the tumor film located inside 
the lateral oblique line was peeled off, a light brown exudate 
was observed from the inside. Tumors taken during the bi-
opsy showed granulation- like tissue (sample size: 8x8mm). 
Proliferation of Langerhans cells with large and distinct cy-
toplasm and coffee bean- like nuclei was observed by hema-
toxylin and eosin staining (Figure  4A). Additionally, many 
eosinophilic infiltrates were involved, and some areas showed 
bleeding, hyperplasia of the capillaries, congestion, and ne-
crotic tissue (Figure 4B). Immunohistochemical (IHC) stain-
ing identified these clusters of cells as Langerhans cells due 
to their intense immunoreactivity for S- 100 protein and CD1a 
(Figure 4C,D). Based on these histopathological findings, to-
gether with the tumor morphology, developmental site, and 
markers, we diagnosed this patient with SS- type LCH.
Surgical intervention was initially planned; however, be-
cause the patient was a child, factors such as jaw growth and 
tooth formation had to be taken into consideration. On the 
other hand, there have been reports of cases in which spon-
taneous remission can be expected in SS- type LCH at the 
bone limit.7 When we performed follow- up, the swelling and 
tenderness of the left cheek disappeared with the disappear-
ance of acute inflammation after biopsy. CT scans taken two 
months after the biopsy showed no apparent exacerbation of 
the lesions (Figure 5A), and a CT scan at six months showed 
a marked reduction in the size of the lesion, regeneration 
of the buccolingual cortex, and no buccolingual periosteal 
response (Figure 5B). In addition, tooth germ formation of 
the left lower second premolar was observed in the lingual 
cortical bone. Consequently, the lesion was considered to 
be healing, and we followed it without additional treatment. 
Eighteen months after the biopsy, the lesion had completely 
disappeared (Figure 5C). Since then, we have continued reg-
ular follow- up, and at the time of writing, it has been 7 years 
with no sign of relapse or onset in other organs.
3 |  DISCUSSION
LCH is a condition that results from the monoclonal expan-
sion of immunophenotypically and functionally immature 
Langerhans cells.9 In recent years, Langerhans cells present 
in LCH lesions have come to be referred to as LCH cells and 
F I G U R E  1  Clinical features at 
first visit. A, The left mandibular region 
was diffusely swollen. B, An intraoral 
photograph shows no obvious abnormality
(A) (B)
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are often distinguished from those in the epidermis because 
there are obvious differences in phenotype, genetic abnor-
mality, and morphological findings,10,11 The cause of LCH 
is unknown, and it is not still fully understood whether it is 
neoplastic or responsive. LCH cells tend to have mutations 
in the BRAF gene. Therefore, it is considered that the thera-
peutic effect of BRAF- specific agents can be expected.12 It 
has been reported that vemurafenib monotherapy for high- 
risk infant LCH who was positive for BRAF V600E muta-
tion and refractory to vinblastine and cladribine was rapidly 
effective.13 Some research mentioned that LCH may have a 
neoplastic aspect.14 It was reported that the BRAF V600E 
mutation, which is a carcinogenic mutation, was found in 
LCH cells in about half of the cases and that phosphoryla-
tion of ERK protein was enhanced in almost all cases even 
in cases without BRAF mutation.15 On the other hand, there 
was reported that LCH may mimic several oro- facial inflam-
matory and neoplastic diseases.16 At the lesions of LCH, not 
only LCH cells, but also various inflammatory cells such as 
eosinophils, lymphocytes, macrophages, and osteoclast- like 
polynuclear giant cells are infiltrated. Serum from LCH pa-
tients has elevated levels of the soluble interleukin- 2 (IL- 2) 
receptor, a T- cell activation marker, and receptor activator of 
nuclear factor kappa- B ligand (RANKL), an osteoclast acti-
vator, by reflecting cytokines/chemokines secretion from the 
lesion site.17 Especially in high- risk LCH patients, osteopon-
tin (OPN), IL- 18, and CCL2, which are representative of in-
flammatory cytokines/chemokines, are elevated.18 Excessive 
secretion of cytokines/chemokines and activation of osteo-
clasts are expected to lead to tissue destruction.19 LCH is 
classified into three types according to the site of occurrence 
and disease type. In the present case, SS- type LCH, known as 
F I G U R E  2  Radiological features. 
A, B, CT scan showing osteolysis with 
indistinct borders in the left mandible. A 
rupture (arrowhead) and periosteal reaction 
(arrow) was found in the buccolingual 
cortical bone. C, Contrast- enhanced MRI 
T1- weighted imaging showing a mass 
extending outside the buccolingual bone. D- 
F, Bone scintigraphy and PET- CT showing 




F I G U R E  3  A, B, Three- dimensional 
model showing osteolysis in the left 
mandible. Arrowheads indicate the location 
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eosinophilic granulomatosis, developed independently in the 
mandible. The frequencies of occurrence of the SS, SM, and 
MM types are almost identical, and as the types become more 
multiple and/or multi- organ, the patients tend to be younger, 
and recurrence and mortality tend to increase.4 LCH can 
occur in various sites, and 78% of LCH patients have bone 
lesions.4 Among the incidence of bone lesions, it has been 
reported that the mandible accounts for about 7% to 9% of 
cases and the maxilla accounts for about 1%.4
The clinical manifestations of LCH in the jawbone in-
clude bone pain and swelling, trismus, tooth sway, patholog-
ical fractures, and bone deformities.20 Imaging examinations 
show a solitary or multiple bone punching or bone destruc-
tion with a periosteal reaction,21,22 However, it is not easy to 
discriminate this disease from clinical and imaging findings, 
and the definitive diagnosis is based on pathological find-
ings.23 LCH histopathology shows diffuse or focal growth 
of LCH cells with characteristic coffee bean- like nuclei and 
eosinophilic cytoplasm, accompanied by eosinophil infiltra-
tion. LCH is immunohistologically positive for S- 100 protein 
and CD1a and is characterized by the presence of Birbeck 
granules in the cytoplasm when observed with an electron 
microscope.24
The choice of treatment for LCH depends on the type of 
disease. For the SM and MM types, combination chemother-
apy is often selected. However, the disease can progress rap-
idly and lead to a fatal progress in refractory and recurrent 
cases, and the definitive establishment of a treatment method 
for such cases is much desired. The treatment of SS- type bone 
lesions, on the other hand, has been performed empirically 
F I G U R E  4  Histologic features. A, B, 
Hematoxylin and eosin staining showing 
proliferation of Langerhans cells (arrows) 
with large and distinct cytoplasm and coffee 
bean- like nuclei (A) and infiltration of many 
eosinophils (B). Scale bar: 50 μm. C, D, 
Immunohistochemical staining showing 
immunoreactivity for S- 100 (C) and CD1a 
(D). Scale bar: 50 μm
(A) (B)
(C) (D)
F I G U R E  5  CT images during follow- up at 2 mo (A), 6 mo (B), and 18 mo (C) after biopsy. Tooth germ formation of the left lower second 
premolar was found at a site within the original lesion range (yellow arrow)
(A) (B) (C)
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and has included surgical curettage, local administration of 
steroids, combination chemotherapy, and radiation therapy; 
there is no consensus on treatment to date. It has been re-
ported that a quarter of SS- type bone lesions are expected 
to regress spontaneously.25,26 However, chemotherapy is 
often selected when there are craniofacial lesions other than 
the canopy, which are considered to be at high risk of de-
veloping diabetes insipidus.5 Besides, it has been suggested 
that lesions smaller than 2 cm should be completely curet-
ted at biopsy, lesions measuring 2- 5 cm should be partially 
curetted at biopsy, and lesions larger than 5  cm should be 
observed at biopsy to track their progress.25 There have been 
few reports of spontaneous regression after biopsy of SS- type 
LCH in the mandible,7,27- 29 In the present case, although the 
lesion showed marked progression, we decided to perform 
follow- up, considering the patient's age and the extent of the 
lesion. At 6 months after the biopsy, spontaneous regression 
of the lesion was observed, and no recurrence or complica-
tions have been observed up to the present time, 7 years after 
the biopsy.
Various hypotheses have been proposed for spontaneous 
regression of LCH, including arrested lesion growth due to 
the disappearance of local inflammation,30 decompression 
of lesions by biopsy,27 triggered apoptosis of tumor cells,31 
and more. Although we were unable to clarify the reason for 
spontaneous regression in the present case, our experience 
suggests the effectiveness of follow- up without aggressive 
treatment for SS- type LCH in the jawbone. However, there 
has been a report of a very rare case in which an SS- type 
LCH recurred after showing a healing tendency and pro-
gressed rapidly to a fatal outcome.32 Furthermore, even with 
SS- type LCH, cases in craniofacial bone with soft tissue 
masses convey higher risk of future diabetes insipidus and 
central nervous system disorders compared with cases with 
lesions in other bones,33,34 It is recommended that regular fol-
low- up be performed even after healing.
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